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Abstract Myogenin (a member of the myogenic basic helix- 
loop-helix transcription factor family) seems to be the main effec- 
tor of proliferation repression, a crucial step which precedes mus- 
cle cell terminal differentiation during muscle development. 
Proliferation repression most likely occurs through inhibition of 
proliferation-associated genes such as the proto-oncogene, c-los. 
Here, we demonstrate that myogenin binds to an E-box located 
in the main element of the c-los promoter, the serum response 
element (SRE). Results from co-transfection experiments indi- 
cate that myogenin acts as a repressor for the SRE. Our data 
suggest hat myogenin could play a role in c-los inhibition at the 
onset of muscle cell terminal differentiation. 
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I. Introduction 
Proliferation and differentiation are mutually exclusive proc- 
esses. The balance between the two pathways i controlled both 
by proteins involved in the cellular proliferative response, such 
as proto-oncogenes, and by proteins involved in differentiation. 
This is best illustrated in the muscle model system. In the 
process of muscle cell terminal differentiation, proliferation 
inhibition is a crucial step which precedes muscle-specific gene 
expression and cell fusion into myotubes [1]. Indeed, terminal 
differentiation of myoblastic ell lines in vitro is triggered by 
the accumulation ofthe precursor cells (myoblasts) ina Go state 
[1]. This step is a prerequisite, and a number of mitogens [2 5] 
or oncogenes [6-10] inhibit terminal differentiation. The factors 
which regulate the balance between proliferation and differen- 
tiation in vivo during embryonic development or adult muscle 
regeneration are poorly understood at present. Recent data, 
however, have shed some light on the molecular mechanism 
involved in the control of this delicate balance, which seems to 
be, at least in part, regulated by myogenic factors of the bHLH 
family. Transcription factors from the bHLH family, which are 
instrumental in the muscle cell differentiation process, include 
MyoD [11-13], myogenin [14,15], Myf5 [16] and MRF4/her- 
culin/myf6 [17]. They are all able to elicit in vitro a muscle 
determination program in a number of non-muscle cell types 
[18,19]. These muscle-restricted proteins share a domain of 
homology, the bHLH, which is also common to ubiquitous 
transcription factors uch as the products of the E2A gene, El2 
or E47 [20,21], with which myogenic factors form heterodimeric 
complexes. These heterodimers [22-26] bind to upstream regu- 
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latory sequences of the form CANNTG (E-boxes; [27]) in mus- 
cle-specific gene promoters. MyoD, myogenin and Myf5 are all 
able to transactivate hese promoters efficiently [28], a function 
which involves a common motif in the basic domain [29]. 
In vitro, MyoD, myogenin, MRF4 and Myf5 seem to be 
largely interchangeable, although some differences are ob- 
served (essentially for MRF4; [30-32]). However, in vivo, they 
display largely distinct kinetics and patterns of expression dur- 
ing the course of embryonic development [33 35], suggesting 
that their multiplicity does not reflect a simple redundancy of 
the system. A key role in cell proliferation inhibition had been 
attributed to MyoD. Indeed, MyoD is a target for mitogenic 
differentiation i hibitors [2,7,10]. Moreover, MyoD acts as a 
negative regulator for cell proliferation in vitro [36,37]. Part of 
the mechanism by which MyoD blocks cell proliferation in 
vitro seems to be the repression of proliferation-associated 
genes. In particular, one of the first events associated with 
terminal differentiation is the disappearance of proto-oncogene 
mRNA such as the nuclear proto-oncogene c-fos [38]. c-fos is 
an immediate early, growth factor esponsive gene which is part 
of the AP1 transcriptional complex [39,40] and which is neces- 
sary for bone development and haematopoiesis but not for 
muscle differentiation [41]. In fact, c-fos rather inhibits myo- 
genesis, and when a high level of Fos protein is artificially 
maintained in myoblasts, terminal differentiation is severely 
impaired [7,10]. 
MyoD acts as a repressor of the c-fos promoter, most likely 
through the specific recognition of an E-box, located in the 
c-fos main regulatory sequence, the serum response lement 
(SRE [42]). This E-box is in close proximity to the CArG box, 
a binding site for the serum response factor (SRF). However, 
recent gene knock-out experiments inmice (reviewed in [28,43]) 
suggested that, although MyoD represses proliferation i  vitro, 
it is not a proper target for external (and unknown) anti-prolif- 
erative signals in vivo, and that myogenin isa more appropriate 
candidate for this function. 
Indeed, whereas inactivation of MyoD activity, which re- 
quires inactivation of both MyoD and Myf5 genes [44,45], 
results in a total absence of muscle cells [46], myogenin gene 
disruption results in apparently normal myoblastic precursor 
cells [47] which, however, do not mature into muscle [47,48]. 
Interestingly, myoblasts obtained from mice in which the myo- 
genin gene has been disrupted o form myotubes in vitro when 
deprived of growth factors [48]. Taken together, these data 
suggest that the main step in which myogenin is involved in vivo 
is the terminal step of the process (terminal differentiation is
also, in vitro, the step at which myogenin is induced and re- 
quired [49,50]). They also indicate that a function for which 
myogenin is not replaced by other members of the family in 
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=ig. 1. Myogenin binds to the c-fos E-box with a high affinity. The sequences of the various oligonucleotides u ed as probes or competitors are shown 
n A; the E-box is indicated and the nucleotides mutated in SRE ml are underlined. Myogenin and El2 proteins were in vitro translated separately 
)r together, as indicated, and analysed by EMSA using a probe including the MCK canonical E-box (B and D) or the c-fos E-box (C). B and C were 
-un simultaneously onthe same gel and the myogenin El2 complexes migrated to the same position. In D, the product of a co-translation experiment 
,vas analysed using an MCK probe and various molar excesses of an MCK (lanes 1 and 2), an SRE (lane 3 and 4) or an SRE mutated in the E-box 
lane 5). 
Avo seems to be the block of proliferation which precedes the 
nduction of muscle structural proteins and the fusion into 
nyotubes. Our recent data suggested that proliferation is 
Olocked, at least in part, through the repression of prolifera- 
ion-associated genes such as c-fos [38]. Here, we have tested 
:he hypothesis that myogenin could be as good a repressor of 
the c-fos promoter as MyoD. We demonstrate that myogenin, 
provided that it is in a heterodimeric form, recognises the c-fos 
E-box with a high affinity. Furthermore, forced expression of 
myogenin in N IH  3T3 cells results in c-fos SRE inhibition. This 
function requires the myogenin bHLH region. These results 
suggest that myogenin could be the actual effector of c-fos 
repression at the onset of muscle cell terminal differentiation. 
2. Materials and methods 
2.1. In vitro translation and electrophoretic mobility shift assay 
(EMSA) 
pEMSV El2 [38] and pEMSV myogenin [51] (a kind gift of Dr. E. 
Olson) plasmids were in vitro transcribed using T3 RNA polymerase 
and translated using a Promega translation kit, according to the recom- 
mendations of the manufacturer. Double-stranded oligonucleotides in-
cluding an SRE element (top strand: 5' CTAGACAGGATGTCCAT- 
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ATTAGGACATCTGCGTCAGCT) or an MCK downstream canoni- 
cal sequence (top strand: CTAGACCCCAACACCTGCTGCCTT) 
were purified and radiolabeled with y_32p as previously described [52]. 
For EMSA analysis, 2pl of lysate were diluted in 5 pl of buffer D [53] 
and incubated for 10 min at 4°C with 1 pg of poly(dG:dC) and then 
for 15 min at room temperature with 2 ng of radiolabeled oligonucleo- 
tide in the presence, when indicated, of an excess of unlabeled oligonu- 
cleotide as a competitor. Samples were analysed on a 4% non-denatur- 
ing gel, dried and autoradiographed as described [38]. Results were 
quantified by densitometry analysis of adequate exposures of autoradi- 
ograms. 
2.2. Plasmids 
pEMSV El2 and pSRE CAT were as described in [38]. pEMSV- 
myogenin was a kind gift of Dr. E. Olson. pEMSV A(71-96)-myogenin 
and pEMSV A(71-163)-myogenin were constructed using a PCR 
(polymerase chain reaction) amplified insert. The internal primers were 
TGCAAGGTGCACAGCGCCTCCTGCAG and GGCGCTGTGC- 
ACCTTGCATGCCCACG for pEMSV A(71 163)-myogenin and T- 
GCAAGGTGGTGAATGAGGCCTTCGAGG and CTCATTCAC- 
CACCTTGCATGCCCACG for pEMSV A(71-96)-myogenin. The 
forward external primer included a consensus translation start site [54], 
and both forward and reverse external primers included an EcoRI 
restriction site for cloning convenience. The sequences of these primers 
were: GGAATTCACCATGGAGCTGTATGAGACATCCC (for- 
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-99 +1 
] myo~nln expmulon I 
wt 
MSV myogenln 
~/#////,.~//////~//////////~ k'~b HLH 
I 
I 
I I 
~714HI )  ~.//////////////////////H//~ 
A(71-163) 
A 
I I I I I I I ' - - " '~  
ward) and GGGGGGAATTCAGTTGGGCATGGTTTCG (reverse). 
These constructs were controlled by partial sequencing (which did not 
show any mutations), and results obtained with these constructs were 
confirmed using two independent clones. 
2.3. Cells and transfections 
NIH 3T3 cells were maintained in DMEM supplemented with antibi- 
otics (a mixture of penicillin and streptomycin from Gibco, used ac- 
cording to the manufacturer's ecommendations) and 5% FCS (fetal 
calf serum). Cells were transfected by electroporation as described 
previously [38]. Briefly, cells were harvested by scraping, washed and 
resuspended in 150 ,ul of DMEM (Dulbecco's minimal essential me- 
dium) supplemented with 0.5% FCS. 2/lg of SRE-CAT, indicated oses 
of pEMSV-E12, pEMSV-myogenin or mutants, and 1/lg of RSV-Iuc 
(a construct including the luciferase reporter gene under the control of 
the Rous sarcoma virus long terminal repeat), as an internal control for 
transfection efficiency, were added. After electrical shock (using a 
Bio-Rad apparatus at 960/zF and 200 V), each sample was divided into 
two aliquots and cells were maintained in DMEM 0.5% FCS for 48 h, 
after which one of the aliquots was treated with 20% serum for 4 h. Cells 
were harvested and extracts were standardized based on the luciferase 
activity of the non-serum-treated sample (samples from the same trans- 
fection were standardized based on the protein content, as measured 
by a Bio-Rad assay). CAT activity was measured using [~4C]chloram- 
phenicol and standard procedures, with a 4 h assay. 
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Fig. 2. Myogenin represses the c-fos promoter. NIH 3T3 cells were co-transfected with an SRE-CAT reporter construct together with an EMSV-driven 
expression vector for myogenin, El2 or a mixture of both, as indicated (the constructs used are described in A; the vehicle pEMSV scribe ~2 was 
used in the controls). Cells were cultured in low serum for 48 h and then treated (lanes +) or not (lanes -)  with 20% serum for 4 h. (B) Myogenin 
and E 12 act synergistically (dose of each expression vector used was 1/.tg); (C) inhibition by myogenin/E 12 is dose dependent; (D) inhibition requires 
integrity of the bHLH domain of myogenin (dose of each expression vector used was 1/lg). 
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3. Results and discussion 
.~. 1. Myogenin/E12 heterodimers bind to an E-box in c-fos SRE 
In order to test whether myogenin can recognise an E-box 
m the c-fos promoter, we have analysed in vitro translated 
proteins by an electrophoretic mobility shift assay (EMSA; Fig. 
). Myogenin and El2 proteins were in vitro translated sepa- 
ately or together and analysed for E-box recognition using an 
:+-box from muscle creatine kinase (MCK) or the c-Jos pro- 
~noter (Fig. 1A). As expected [26], myogenin did not bind to the 
rICK E-box with a high affinity, and binding was detectable 
,,nly when El2 and myogenin were co-translated (Fig. 1B). 
~;imilar esults were obtained with the c-fos E-box (Fig. 1C). 
7he lysates programmed with both El2 and myogenin formed 
+ complex with c-fos SRE oligonucleotide, whereas no complex 
vas detectable when each protein was translated separately. 
~ompetition experiments (Fig. ID) indicated that the affinity 
~f myogenin/E12 heterodimers for MCK and c-fos E-boxes 
vere of the same order of magnitude. Indeed, when used as 
mlabeled competitor, similar molar excesses of both probes 
vere needed to observe a significant inhibition. Quantification 
~f competition results suggested that myogenin/E12 heterod- 
mers display an affinity for the c-Jos E-box which is about 2 5 
01d smaller than their affinity for the MCK canonical E-box. 
faken together, these results indicate that myogenin acquires 
t high affinity for the c-fi~s E-box upon hetero-dimerization 
vith El2, as was demonstrated for MyoD [38]. 
~.2. Myogenin/E12 hyper-expression results in c-fos promoter 
repression 
In order to assess whether myogenin can exert an inhibitory 
~ffect on the c-fos promoter, as we have demonstrated for 
VlyoD [38], myogenin was assayed for c-fos SRE modulation 
n a transient co-transfection assay (Fig. 2). NIH 3T3 fibrob- 
asts, which do not express any of the myogenic bHLH pro- 
eins, were used as recipients for these experiments. Ceils were 
ransfected with a reporter construct including the c-fos SRE 
n front of a c-fos minimal promoter (Fig. 2A) [38], together 
vith pEMSV-E12 (an expression vector for El2), pEMSV- 
nyogenin (an expression vector for myogenin), or both; 
;~EMSV-scribe ~2, the vehicle, was used as the control. Results 
Fig. 2) were in good correlation with data obtained by EMSA 
malysis. Co-transfection f each expression vector independ- 
'+ntly did not have any effect on the reporter CAT (chloram- 
)henicol acetyl-transferase) g ne expression, whereas co-trans- 
'ection of both plasmids virtually abolished the reporter e- 
.ponse to serum (Fig. 2B). Note that a significant inhibitory 
'ffect could be observed with pEMSV-myogenin alone when 
times more expression vector was used (data not shown). The 
nhibition was dose dependent (Fig. 2C). Similar to what has 
)een demonstrated for MyoD [38], the inhibition required the 
ntegrity of the bHLH domain: two mutants (described in Fig. 
'.A) in which the basic domain (A71-96) or the whole of the 
msic helix-loop-helix domain (A71-163) had been deleted (and 
vhich had lost the ability to dimerise and to bind to DNA; data 
lot shown), did not inhibit c-fos SRE activity (Fig. 2D). Re- 
~ression by myogenic proteins thus involves the bHLH do- 
main. The precise mechanism of this repression is currently 
+mder investigation and our data suggest that this mechanism 
might be complex. The CArG-box (binding site for SRF) and 
~he E-box (binding site for myogenic bHLH proteins) overlap, 
and binding of these factors is mutually exclusive [38]. How- 
ever, our recent data suggest that a physical interaction between 
SRF and myogenic bHLH could also be involved (Trouche t 
al., submitted). 
Taken together, these data demonstrate that myogenin binds 
to and represses the c-fos promoter, a function which, in vitro, 
myogenin shares with MyoD. In vivo, however, myogenin 
seems to be a better candidate as an effector molecule of c-fos 
inhibition during muscle cell terminal differentiation. 
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